In the newly released "Paediatric drug optimization for respiratory syncytial virus (PADO-RSV) meeting report" by Global ...

Two monoclonal antibodies appeared safe and tolerable when administered alone or in combination to newborns exposed to HIV, according to a proof-of-concept study presented at the International AIDS ...

The flu season is ramping up with more cases, more hospital admissions and more patients sent to intensive care units.

WHO includes ArkBio' paediatric RSV drug, ziresovir in PADO-RSV priority list: Shanghai, China Thursday, July 17, 2025, 14:00 Hrs [IST] Shanghai Ark Biopharmaceutical Co., Ltd. (A ...

Nigeria carries the highest burden of cervical cancer in Africa and ranks seventh globally, with an estimated 12,000 new ...

Multinational pharmaceutical company, MSD has renewed its commitment to strengthening healthcare access in Nigeria, calling ...

In the province of Pinar del Río, five municipalities have been identified as high-risk zones due to a surge in suspected dengue cases, as reported ...

Sanofi has struck a deal to buy Vicebio for $1.15 billion upfront, securing preclin | Sanofi has struck a deal to buy Vicebio ...

A new UK study shows that vaccinating pregnant women against RSV has led to a staggering 72% drop in hospitalizations of newborns with severe lung infections. By passing virus-fighting antibodies to ...

Winter is here, and with it come higher rates of respiratory illnesses. If you've been struck down recently with a sore ...

The FDA has accepted for review the sBLA to expand the indication of Arexvy (RSV vaccine, adjuvanted) to adults aged 18 to 49 years who are at increased risk.